Legend Biotech 

Legend Biotech 

Yahoo Finance • 15 days ago

2 Biotech Stocks Worth Buying Before Their Potential Buyouts

Dealmaking is back with a vengeance in the pharmaceutical sector this year. According to a report by PwC, there were more than $65 billion in pharma and life sciences mergers & acquisitions in the first quarter, the best quarter for the se... Full story

Yahoo Finance • 18 days ago

After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching

Quick Read Legend Biotech (LEGN) generates $1 billion in CAR-T revenue with J&J already embedded as acquirer, yet trades at roughly half its $58 analyst price target. Aleniglipron posted 16% placebo-adjusted weight loss at 44 weeks, placi... Full story

Yahoo Finance • 25 days ago

Legend Biotech shares slide post-pricing of $226M public offering at $29.35 per unit

Legend Biotech (LEGN [https://seekingalpha.com/symbol/LEGN]) has announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20555961-legend-biotech-corporation-announces-pricing-of-public-offering] of 7.7M Americ... Full story

Yahoo Finance • 25 days ago

Legend Biotech Prices $226 Million Public Offering; Stock Down

(RTTNews) - Legend Biotech Corporation (LEGN) has priced an underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per ADS, raising approximately $226 million in gross proceeds before underwriting discounts... Full story

Yahoo Finance • 25 days ago

Legend Biotech Corporation Announces Pricing of Public Offering

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,... Full story

Yahoo Finance • 29 days ago

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependent in vivo CAR-Texpansion without lympho... Full story

Yahoo Finance • last month

Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK

The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $... Full story

Yahoo Finance • last month

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

(RTTNews) - Tuesday's top gainers in the healthcare sector included Bluejay Diagnostics, which inked a strategic partnership with Argonaut; Picard Medical, which is advancing its next-generation Emperor Total Artificial Heart; and Cingulat... Full story

Yahoo Finance • 2 months ago

A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals

First Beijing Investment Ltd disclosed a new position in Legend Biotech(NASDAQ:LEGN), acquiring 2,296,335 shares in the first quarter, with the estimated trade valued at $43.78 million based on average quarterly pricing, according to a May... Full story

Yahoo Finance • 2 months ago

With YMM Down 29%, First Beijing Bought 13 Million More Shares

First Beijing Investment Ltd disclosed in a May 13, 2026, SEC filing that it bought 13,384,327 shares of Full Truck Alliance(NYSE:YMM), an estimated $127.30 million trade based on quarterly average pricing. What happened According to a S... Full story

Yahoo Finance • 2 months ago

Legend Biotech Q1 Earnings Call Highlights

Legend Biotech logo Key Points Interested in Legend Biotech Corporation Sponsored ADR? Here are five stocks we like better. CARVYKTI sales surged in Q1 2026, with net trade sales of about $597 million, up 62% year over year. Growth was d... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * JD.com (JD [https://seekingalpha.com/symbol/JD]) * Sea Limited (SE [https://seekingalpha.com/symbol/SE]) * D-Wave Quantum (QBTS [https://seekingalpha.com/symbol/QBTS])... Full story

Yahoo Finance • 2 months ago

Is Yum China a Buy After Investment Firm Matthews Purchased Shares Worth $12.57 Million?

What happened According to its SEC filing dated May 4, 2026, Matthews International Capital Management LLC purchased 242,785 additional shares of Yum China(NYSE:YUMC) in the first quarter. The estimated value of this activity is $12.57 m... Full story

Yahoo Finance • 2 months ago

H.C. Wainwright Reaffirms Buy Rating for Legend Biotech (LEGN)

Legend Biotech Corp. (NASDAQ:LEGN) is one of the 10 best biotech stocks with highest upside potential. On April 20, H.C. Wainwright maintained its Buy rating for Legend Biotech Corp. (NASDAQ:LEGN). The firm has projected a target price of... Full story

Yahoo Finance • 3 months ago

Legend Biotech (LEGN) Gets Bullish Ratings, PT Hike, Soars 18%

Legend Biotech Corp. (NASDAQ:LEGN) is one of the 10 Stocks With Double-Digit Returns. Legend Biotech soared for a 5th straight day on Monday, climbing 18.42 percent to close at $25.07 apiece, as investors took heart from two investment fi... Full story

Yahoo Finance • 3 months ago

Legend Biotech (LEGN) Q4 2024 Earnings Transcript

Image source: The Motley Fool. Legend Biotech (LEGN) Q4 2024 Earnings Call Transcript DATE Tuesday, March 11, 2025 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Ying Huang Interim Chief Financial Officer — Jessie Yeung Pres... Full story

Yahoo Finance • 3 months ago

RBC Capital Cuts PT on Legend Biotech Corporation (LEGN) to $62 From $66 – Here’s Why

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best high growth healthcare stocks to buy now. RBC Capital cut the price target on Legend Biotech Corporation (NASDAQ:LEGN) to $62 from $66 on March 11, reiterating an Outperform ratin... Full story

Yahoo Finance • 4 months ago

This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half

On February 17, 2026, HHLR Advisors reported selling 1,607,930 shares of Futu Holdings(NASDAQ:FUTU), an estimated $276.00 million transaction based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story

Yahoo Finance • 4 months ago

Legend Biotech Q4 Earnings Call Highlights

Legend Biotech logo Key Points CARVYKTI net trade sales were about $555 million in Q4 (up 66% YoY), and management said CARVYKTI reached profitability in 2025 with the company expecting enterprise-wide profitability in 2026. The therapy... Full story

Yahoo Finance • 5 months ago

HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model

Key Points HHLR Advisors, Ltd sold 1,641,000 shares of Baidu; estimated trade size was $216.23 million based on average pricing for the quarter Quarter-end position value declined by $216.23 million, reflecting both the share sale and cha... Full story